Marker Therapeutics, Inc. (MRKR)
2.09
+0.05
(+2.45%)
USD |
NASDAQ |
Jan 23, 16:00
2.09
0.00 (0.00%)
After-Hours: 19:07
Marker Therapeutics Research and Development Expense (TTM): 14.74M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Viridian Therapeutics, Inc. | 321.22M |
| ADMA Biologics, Inc. | 3.776M |
| Kiniksa Pharmaceuticals International Plc | 97.30M |
| Neurocrine Biosciences, Inc. | 936.90M |
| AIM ImmunoTech, Inc. | 3.826M |